Indoco Remedies received USFDA nod for two of its facilities in Goa. The US health regulator has approved the sterile facility (plant-II) and solid dosage facility (plant -III) located at Verna.

The nod will facilitate the generic approvals in the US market and subsequent product launches there and will boost high-margin revenues from the highly remunerative US market.

Shares of the company gained Rs 23.2, or 14.1%, to trade at Rs 187.75. The total volume of shares traded was 200,376 at the BSE (10.58 a.m., Tuesday).